John Hussman's HALO Position Overview
John Hussman (via Hussman Strategic Advisors, Inc.) currently holds 31.5K shares of Halozyme Therapeutics, Inc. (HALO) worth $2.31 M, representing 0.50% of the portfolio. First purchased in 2022-Q2, this medium-term investment has been held for 14 quarters.
Based on 13F filings, John Hussman has maintained a strategic position in HALO, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2024, adding 31.5K shares. Largest reduction occurred in Q3 2025, reducing 52.5K shares.
Analysis based on 13F filings available since 2013 Q2
John Hussman's Halozyme Therapeutics (HALO) Holding Value Over Time
Track share changes against reported price movement
Quarterly Halozyme Therapeutics (HALO) Trades by John Hussman
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2022 | +9,300 | New Buy | 9,300 | $43.98 |
| Q3 2022 | +21,700 | Add 233.33% | 31,000 | $39.55 |
| Q4 2022 | -6,200 | Reduce 20.00% | 24,800 | $56.90 |
| Q1 2023 | +21,700 | Add 87.50% | 46,500 | $38.19 |
| Q3 2023 | -15,000 | Reduce 32.26% | 31,500 | $38.20 |
| Q2 2024 | +10,500 | Add 33.33% | 42,000 | $52.36 |
| Q4 2024 | +31,500 | Add 75.00% | 73,500 | $47.81 |
| Q2 2025 | +10,500 | Add 14.29% | 84,000 | $52.02 |
| Q3 2025 | -52,500 | Reduce 62.50% | 31,500 | $73.34 |
John Hussman's Halozyme Therapeutics Investment FAQs
John Hussman first purchased Halozyme Therapeutics, Inc. (HALO) in Q2 2022, acquiring 9,300 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
John Hussman has held Halozyme Therapeutics, Inc. (HALO) for 14 quarters since Q2 2022. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
John Hussman's largest addition to Halozyme Therapeutics, Inc. (HALO) was in Q4 2024, adding 73,500 shares worth $3.51 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, John Hussman's firm, Hussman Strategic Advisors, Inc., owns 31,500 shares of Halozyme Therapeutics, Inc. (HALO), valued at approximately $2.31 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Halozyme Therapeutics, Inc. (HALO) represents approximately 0.50% of John Hussman's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
John Hussman's peak holding in Halozyme Therapeutics, Inc. (HALO) was 84,000 shares, as reported at the end of Q2 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.